The Ritedose Corporation’s cover photo
The Ritedose Corporation

The Ritedose Corporation

Pharmaceutical Manufacturing

Columbia, SC 6,286 followers

Manufacturing | Inhalation | Ophthalmics | Sterile Liquids

About us

The Ritedose Corporation is a leader in blow-fill-seal(BFS) manufacturing of small fill volume pharmaceutical unit dose sterile and non-sterile liquids. We specialize in manufacturing inhalation products, eye drops, eardrops and unit dose oral liquids.

Industry
Pharmaceutical Manufacturing
Company size
501-1,000 employees
Headquarters
Columbia, SC
Type
Privately Held
Founded
1995
Specialties
Contract Pharmaceutical Blow-Fill-Seal Manufacturer

Locations

Employees at The Ritedose Corporation

Updates

  • In 2025, look for sustainability. This year, drug manufacturers will seek sustainability measures that reduce carbon footprints and reduce energy use and waste. Blow-Fill-Seal (BFS), an automated process that Ritedose specializes in, forms containers, fills them, and seals them all in one step. And it can help meet these environmental goals. BFS automation uses less energy and makes production lines more compact, increasing efficiency. BFS also needs less water and produces less waste than traditional aseptic packaging. Learn more at Ritedose.com Ritedose: Passion and precision with a purpose.

  • Innovation is shaping the future of CDMO and generics manufacturing, and Ritedose is leading the way. We’re honored to be featured in Contract Pharma, where Ritedose CEO, Jody Chastain shares insights on how advanced manufacturing, expertise, and cutting-edge technologies—like AI and Blow-Fill-Seal (BFS)—are driving success in an evolving pharmaceutical landscape. With a strong track record of innovation and a commitment to quality, Ritedose continues to deliver life-saving medications efficiently, safely, and reliably. 🔗 Read the full article here: https://loom.ly/FE1SkEk Ritedose: Passion & Precision with a Purpose Ritedose.com

    • No alternative text description for this image
  • Is BFS right for you? This year, we expect a heightened demand increase in Blow-Fill-Seal (BFS) technology for single-dose liquid medications, as companies prioritize sterility and efficiency in production. Recently, Verona Pharma, which received US FDA approval for Ohtuvayre (TM), a novel product for chronic obstructive pulmonary disease (COPD), partnered with us because of our leading BFS capabilities and expertise in respiratory medications. To meet the demands of this new drug, Ritedose expanded its manufacturing capacity by 180 million doses, and installed a packaging line that doubles our ability to deliver single vial medications.

    • No alternative text description for this image
  • Last week marked the start of our 1,000 Hours of Purpose initiative! Ritedose employees rolled up their sleeves at Harvest Hope Food Bank to make a direct impact. Together, we’re dedicating our time, skills, and energy to help those in need...one hour at a time. These opportunities remind us that we are all part of the same community, facing the same challenges as our friends and neighbors. Follow along as we work together to reach 1,000 hours of purpose in 2025. A career full of growth. A life full of impact. #LifeAtTheDose #1000HoursofPurpose

  • The Ritedose Corporation reposted this

    The annual College of Pharmacy Graduate Research Symposium showcases the work of our talented Ph.D. candidates in Drug Discovery & Biomedical Sciences and Pharmaceutical Outcomes Sciences 🔬 This year's event featured insightful presentations, a dynamic faculty panel, and the presentation of our graduate student awards. Congratulations to our award recipients and a special thank you to our friends at The Ritedose Corporation for their generous sponsorship of this event! -Kim-Tuyen Huynh Dam – Outstanding Graduate Student of the Year -Xiangxiang Jiang – Charles Yandell Award -Eugene Lee – James Plaxco, Jr. Award -George Merhej – Daniel Li Chang-Wang Scholarship -Abby Davies and Zachary Stryker – Ritedose Corporation Graduate Student Scholarship

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
      +2
  • 2025 will be transformative for drug manufacturing. Advancements in technology, new regulatory demands, and a greater focus on sustainability will require us to adapt, but also usher in new opportunities. These transformations will be particularly important for blow-fill-seal (BFS) technology. An automated process that combines drug container forming, filling and sealing in one step, BFS-made syringes and injectors are enhancing drug delivery. When seeking a manufacturing partner, it’s going to be important to understand the viability of BFS-produced medications.

    • No alternative text description for this image
  • At Ritedose, we’re taking action. Our employees are volunteering 1,000 hours of company time to support the Midlands community. We’re partnering with United Way of the Midlands (SC) to tackle some of the biggest challenges facing our neighbors: housing, education, homelessness, workforce development, food security, and senior care. This isn’t just a donation. It’s 1,000 hours of hands-on impact. Together, we’re making change — one hour at a time. Want to learn more? Check out the full release here: https://loom.ly/2rs-4w8

    • No alternative text description for this image
  • Ritedose Pharmaceuticals is here at ECRM’s generics Rx session! This is not your typical trade show. No booths, no exhibitors, no sales pitches. Instead, ECRM arranges personal meetings between sellers (that’s us) and buyers (that’s you) during the session. If you’re here, be sure to find Paula Miller and talk with us about Ritedose Pharma's safe, efficient and reliable generics manufacturing. Learn More: https://lnkd.in/efViJp9X

Similar pages

Browse jobs